Our Role Models & Case Studies

Innovation in science takes many forms. Be it a tweak that improves technology or a protocol, all the way to the development of new platforms and therapeutics which are the cornerstones of Biotech companies. Translating science at Sanger is about impact, closing the gaps in technologies that will continue to improve health and biodiversity.

Read about them here.

Accidental Entrepreneur

Sanger Director Matt Hurles defines himself as an accidental entrepreneur, even though he spearheads a number of innovative initiatives that showcase his motivation to ultimately bring benefits to patients, with a clear focus on rare developmental disorders.

Find out more

Microbiotica: Unlocking the power of the human genome

Based originally upon the research of the human microbiome carried out at the Wellcome Sanger Institute, Microbiotica was spun out as a microbiome therapeutics company in 2016.

Find out more

A passion for problem-solving

Qianxin Wu is at the forefront of innovation, working on CRISPR, genome editing and single-cell technologies, amongst other things. She is a highly entrepreneurial scientist, with a passion for problem solving.

Find out more

Congenica: Advancing healthcare through Genomics

Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres, and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.

Find out more

Sequencing anything, anytime, anywhere

Physilia Chua is a postdoctoral fellow leading the BIOSCAN flying insects project in the UK and her work documents UK insect diversity and the discovery of species interactions.

Find out more

Mosaic's Becoming

Mosaic Therapeutics exemplifies how our research can have a veritable impact on society. We, at the Wellcome Sanger Institute, are committed to innovative science at scale, but we need partners and investors to transfer this science into the clinic. 

Find out more

Tackling trypanosomiasis in cattle in sub-Saharan Africa

Three vaccine targets discovered by the Wellcome Sanger Institute focus on targeting animal trypanosomiasis in an effort to find a cure for a disease that causes billions in economic losses in one of the poorest regions on earth. These losses fall heavily on small holders, who are often heavily dependent on livestock for their livelihood.

Find out more

From bench to bedside – Innovating blood cancer clinical practice

Jyoti Nangalia, Faculty member and haematologist at the Cambridge University Hospitals NHS Trust is at the forefront of innovation in blood cancers, combining her clinical, academic and genomic expertise to advance our understanding of blood cancers.

Find out more

Kymab: Novel antibody therapeutics at Sanger’s first ever spin-out

The Wellcome Sanger Institute‘s first-ever spin-out, Kymab Ltd was acquired by Sanofi in 2021. Founded by the former Institute director and Sanger researcher, Allan Bradley, Kymab’s therapeutics are designed to modulate the immune system to overcome cancer immune tolerance and to treat autoimmune diseases. A great example of the power of innovation and technology translation.

Find out more

From somatic mutations to Quotient

Dr Iñigo Martincorena, group leader in the Cancer, Ageing and Somatic Mutation programme at the Wellcome Sanger Institute and academic co-founder of Quotient Therapeutics. 

Find out more

COSMIC: Commercialising a database

The Catalogue Of Somatic Mutations In Cancer - a database curated by experts covering a wide variety of somatic mutation mechanisms involved in human cancer. 

Find out more

Three ambitious projects to fight Malaria

Between 2012 and 2017, the Sanger Institute's Genomics Innovation backed three ambitious projects tackling areas key to eliminating malaria. 

Find out more

 

 

 

Genomics Innovation team

The Genomics Innovation team at the Sanger Institute works to empower future innovators. 

Meet the team